National Stockpiles Affect Medicine Access in Some EU Countries
Medicines for Europe shared on LinkedIn:
”Fragmented national stockpiling policies are making essential medicines harder to access in some EU countries, extending shortages and exposing our internal market.
In Germany, a 6-month stockpile equals almost 2 years’ supply for the Netherlands. Uncoordinated stockpiling risks destabilizing smaller markets and reducing treatment availability in other regions.
For example, 70% of companies have observed longer stockout periods and reduced availability of medicines in smaller markets, due to stockpiling requirements.
We need a unified approach to ensure timely and equal access for patients, as well as robust supply chains based on proportionate measures and EU solidarity.
Check out our report to learn more.”
Find more posts on Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome